Time-limited venetoclax, obinutuzumab and ibrutinib or venetoclax plus obinutuzumab prolonged PFS compared with chemoimmunotherapy among fit, previously untreated patients with chronic lymphocytic leukemia, according to study results.
The preplanned interim analysis of the international, randomized phase 3 GAIA/CLL13 trial, presented during European Hematology Association Hybrid 2022 Congress, also showed patients with unmutated immunoglobulin heavy-chain variable (IGHV) status appeared to benefit most from targeted therapy.
In Europe, EHA guidelines inform decisions on front-line treatment of